ロテマックスSMの薬剤に関する洞察と市場予測：2032年

ロテマックスSM（ロテプレドノールエタボネート点眼液、0.38%）は、眼科手術後の炎症と疼痛を適応とするコルチコステロイドで、ロテマックスの新剤形です。ロテマックスゲル（0.5％）と比較して、ロテマックスSMはサブミクロンの粒子径で、涙液中への薬物の溶出を速めます。ロテマックスSMはLOTEMAX Gelに比べて房水への浸透性が2倍優れています。ロテマックスSMの承認により、医師は眼科手術後の炎症と疼痛を治療するための最先端のロテプレドノールエタボネート製剤を患者に処方することができます。

当レポートでは、米国におけるロテマックスSM市場について調査し、市場の概要とともに、2023年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 急性疼痛におけるロテマックスSMの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制上のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 ロテマックスSM市場評価

• 急性疼痛におけるロテマックスSMの市場展望
• 米国の分析
  • 米国における急性疼痛治療薬ロテマックスSMの市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

• 参考文献
• レポート調査手法

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: LOTEMAX SM, Clinical Trial Description, 2023
• Table 2: LOTEMAX SM, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: LOTEMAX SM Market Size in the US, in USD million (2019-2032)

List of Figures

• Figure 1: LOTEMAX SM Market Size in the United States, USD million (2019-2032)

"LOTEMAX SM Drug Insight and Market Forecast - 2032" report provides comprehensive insights about LOTEMAX SM for acute pain in the United States. A detailed picture of the LOTEMAX SM for acute pain in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the LOTEMAX SM for acute pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the LOTEMAX SM market forecast analysis for acute pain in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in acute pain.

Drug Summary:

LOTEMAX SM (loteprednol etabonate ophthalmic gel; 0.38%) is a corticosteroid indicated for treating postoperative inflammation and pain following ocular surgery; this is a new formulation of LOTEMAX. Compared to Lotemax Gel (0.5%), LOTEMAX SM delivers a submicron particle size for faster drug dissolution in tears. LOTEMAX SM provides two times greater penetration to the aqueous humor than LOTEMAX Gel. With its approval, physicians could prescribe patients the most advanced loteprednol etabonate formulation for treating postoperative inflammation and pain following ocular surgery.

Mechanism of action

Loteprednol etabonate is a corticosteroid, and corticosteroids have been shown to inhibit the inflammatory response to various inciting agents. It delivers a submicron particle size that dissolves faster in tears than LOTEMAX Gel (loteprednol etabonate ophthalmic gel 0.5%) and provides double the penetration to the aqueous humor.

Dosage

The closed bottle is inverted and shaken once to fill the tip before instilling drops.

One to two drops of LOTEMAX are applied into the conjunctival sac of the affected eye four times daily, beginning the day after surgery and continuing throughout the first 2 weeks of the postoperative period.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the LOTEMAX SM description, mechanism of action, dosage and administration, research and development activities in acute pain.
• Elaborated details on LOTEMAX SM regulatory milestones and other development activities have been provided in this report.
• The report also highlights the LOTEMAX SM research and development activities in acute pain across the United States.
• The report also covers the patents information with expiry timeline around LOTEMAX SM.
• The report contains forecasted sales of LOTEMAX SM for acute pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for acute pain.
• The report also features the SWOT analysis with analyst views for LOTEMAX SM in acute pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

LOTEMAX SM Analytical Perspective by DelveInsight

In-depth LOTEMAX SM Market Assessment

This report provides a detailed market assessment of LOTEMAX SM for acute pain in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.

LOTEMAX SM Clinical Assessment

The report provides the clinical trials information of LOTEMAX SM for acute pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for acute pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence LOTEMAX SM dominance.
• Other emerging products for acute pain are expected to give tough market competition to LOTEMAX SM and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of LOTEMAX SM in acute pain.
• Our in-depth analysis of the forecasted sales data of LOTEMAX SM from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the LOTEMAX SM in acute pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of LOTEMAX SM?
• What is the clinical trial status of the study related to LOTEMAX SM in acute pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LOTEMAX SM development?
• What are the key designations that have been granted to LOTEMAX SM for acute pain?
• What is the forecasted market scenario of LOTEMAX SM for acute pain?
• What are the forecasted sales of LOTEMAX SM in the United States?
• What are the other emerging products available and how are these giving competition to LOTEMAX SM for acute pain?
• Which are the late-stage emerging therapies under development for the treatment of acute pain?

Table of Contents

1. Report Introduction

2. LOTEMAX SM Overview in Acute pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. LOTEMAX SM Market Assessment

• 5.1. Market Outlook of LOTEMAX SM in Acute pain
• 5.2. The United States Analysis
  • 5.2.1. Market Size of LOTEMAX SM in the United States for Acute pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options